Becton, Dickinson and Company logo BDX - Becton, Dickinson and Company

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 16
HOLD 17
SELL 1
STRONG
SELL
0
| PRICE TARGET: $173.19 DETAILS
HIGH: $204.00
LOW: $159.00
MEDIAN: $168.01
CONSENSUS: $173.19
UPSIDE: 17.31%

About Becton, Dickinson and Company (https://www.bd.com)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Key Executives

NAME TITLE DOB SALARY
Thomas E. Polen Jr. President, Chief Executive Officer & Chairman 1973 $3,588,724 USD
Michael C. Feld Executive VP & Chief Revenue Officer 1981 $1,910,642 USD
Vitor Roque Executive Vice President & Chief Financial Officer 1983 $1,777,376 USD
Richard Byrd Executive Vice President & President of Interventional Segment 1968 $1,406,554 USD
Michael Garrison Executive VP & President of Medical Segment and BioPharma Systems Segments 1969 $1,360,526 USD
Carla Burigatto Senior Vice President & Chief Communications Officer
Claudia Curtis Senior Vice President, Chief Ethics & Compliance Officer
Denise Fleming Executive Vice President & Chief Information Officer 1971
Elizabeth McCombs Executive Vice President & Chief Technology Officer 1977
Joseph Smith Senior Vice President & Chief Scientific Officer
Lanesha T. Minnix Executive Vice President & General Counsel 1975
Pamela L. Spikner Senior Vice President, Chief Accounting Officer & Controller 1977
Shawn C. Bevec Senior Vice President of Investor Relations

Company Peers

Peer analysis pending, check back in 1-2 minutes.